Cadence Pharmaceuticals Inc. (CADX)

[surf1944]

7:35AM Cadence Pharma sees Q4 net product rev from OFIRMEV above ests, FY13 in-line (CADX) 5.00 : Co issues upside guidance for Q4 (Dec), sees Q4 (Dec) net product rev from OFIRMEV of ~$17.1 mln vs. $16.26 mln Capital IQ Consensus Estimate.

Co issues in-line guidance for FY13 (Dec), sees FY13 (Dec) net rev from OFIRMEV of ~$94-100 mln vs. $96.58 mln Capital IQ Consensus Estimate.